Gilead Sciences Inc diskutieren
Gilead Sciences Inc
WKN: 885823 / Symbol: GILD / Name: Gilead Sciences / Aktie / Biotechnologie & medizinische Forschung / Large Cap /
66,92 €
-1,51 %
Gilead Stock Pops nach Covid Drug bringt 2020 einen Umsatz von 2,8 Milliarden US-Dollar
https://www.investors.com/news/technology/gilead-stock-gilead-earnings-q4-2020/
Kursziel geändert auf 64,0
Kursziel geändert auf 65,0
Buy Gilead Sciences Inc
Kursziel geändert auf 67,0
Buy mit Kursziel 60,0
d'accord la résistance à vnr
Die Nachfrage nach Remdesivir in Indien ist enorm und die lokalen Lizenznehmer produzieren mit voller Kapazität
https://www.nasdaq.com/articles/syngene-targets-delivering-500000-vials-of-remdesivir-in-india-as-covid-19-surges-2021-04
http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-announces-steps-expand-availability-remdesivir
Morgen veröffentlich die Company nach Börsenschluss das Quartalsergebnis.
https://www.nasdaq.com/articles/syngene-targets-delivering-500000-vials-of-remdesivir-in-india-as-covid-19-surges-2021-04
http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-announces-steps-expand-availability-remdesivir
Morgen veröffentlich die Company nach Börsenschluss das Quartalsergebnis.
Gilead macht in Q1 16% mehr Umsatz dank der Nachfrage nach Remdesivir - wegen einer Korrektur der Galapagos Bewertung wurde der Ausblick auf das GAAP EPS 2021 gesenkt.
http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-release-first-quarter-2021-financial-results
http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-release-first-quarter-2021-financial-results
- Total first quarter 2021 revenue of $6.4 billion increased 16% compared to the same period in 2020, primarily due to Veklury® (remdesivir) sales, Cell Therapy growth with Yescarta® (axicabtagene ciloleucel) and the U.S. launch of Tecartus® (brexucabtagene autoleucel) in the third quarter 2020, the first full quarter recognition of Trodelvy® (sacituzumab govitecan-hziy 180 mg) sales, and Hepatitis B virus (“HBV”) growth with Vemlidy® (tenofovir alafenamide 25 mg) .
- Diluted Earnings Per Share (“EPS”) increased 12% to $1.37 for the first quarter 2021 compared to the same period in 2020, primarily driven by revenue growth, partially offset by fair value loss adjustments related to Gilead’s equity investment in Galapagos NV (“Galapagos”) and lower interest income.
- Non-GAAP diluted EPS increased 24% to $2.08 for the first quarter 2021 compared to the same period in 2020, primarily due to higher operating income and lower effective tax rate, offset by lower interest income.
- As of March 31, 2021, Gilead had $6.2 billion of cash, cash equivalents and marketable debt securities compared to $7.9 billion as of December 31, 2020.
- During the first quarter 2021, Gilead generated $2.6 billion in operating cash flow.
- During the first quarter 2021, Gilead repaid $1.3 billion of debt, utilized $1.3 billion on acquisitions, net of cash acquired (including in-process research and development (“IPR&D”)), paid cash dividends of $917 million and utilized $309 million on repurchases of common stock.
Link zur Präsentation
http://investors.gilead.com/static-files/9fc6ee8f-b63c-451b-a8a8-9136bdcfc54c
http://investors.gilead.com/static-files/9fc6ee8f-b63c-451b-a8a8-9136bdcfc54c
Sargnagel hat das Wertpapier Gilead Sciences Inc in seinem Wikifolio Instinkt pur gekauft.
Am 29. Juli wird Börsenschluss die Ergebnisse des zweiten Quartals 2021 veröffentlichen
Gilead berichtete am 29.7. - die Ergebnisse sind solide aber nicht berauschend. Die Firma profitiert immer noch von den vielen Covid-19 Behandlungen mit Remdesivir. Während die HIV Umsätze stagnierten, erholten sich die HCV Umsätze gegenüber den sehr niedrigen Vorjahreswerten. Der Umsatz der Zell Therapie wächst schnell, trägt aber anteilig noch nicht signifikant zum Ergebnis bei. Die üppige Dividende gibt es zu jedem Quartalsende. Wegen der aussichtsreichen Entwicklungs-Pipeline und der guten Cash Zuflüsse sehe ich in Gilead ein günstig bewertetes Wachstumsunternehmen.
https://investors.gilead.com/events
https://investors.gilead.com/events
- Total second quarter 2021 revenue of $6.2 billion increased 21% compared to the same period in 2020, primarily due to Veklury® (remdesivir), higher demand for Biktarvy (bictegravir 50 mg/FTC/tenofovir alafenamide 25 mg (“TAF”)) and our hepatitis C virus (“HCV”) products, as well as continued uptake in the United States of Trodelvy® (sacituzumab govitecan-hziy) and Tecartus® (brexucabtagene autoleucel).
- Diluted Earnings Per Share (“EPS”) increased to $1.21 for the second quarter 2021 compared to net loss per share of $2.66 for the same period in 2020. This was primarily driven by the impact of higher in-process research and development (“IPR&D”) expenses in the second quarter 2020 related to the Forty Seven, Inc. acquisition and revenue growth in the second quarter 2021, offset by fair value loss adjustments on Gilead’s equity investment in Galapagos NV.
- Non-GAAP diluted EPS increased 68% to $1.87 for the second quarter 2021 compared to the same period in 2020, primarily due to higher operating income partially offset by lower interest income.
- As of June 30, 2021, Gilead had $7.4 billion of cash, cash equivalents and marketable debt securities compared to $7.9 billion as of December 31, 2020.
- During the second quarter 2021, Gilead generated $2.3 billion in operating cash flow.
- During the second quarter 2021, Gilead paid cash dividends of $894 million and utilized $43 million to repurchase common stock.
Kursziel geändert auf 68,0
Sell mit Kursziel 46,0
Buy mit Kursziel 65,0
Buy mit Kursziel 68,0
Gilead heute mit kursbewegenden Nachrichten
https://investors.gilead.com/news/news-details/2022/Trodelvy-Significantly-Improves-Overall-Survival-in-Pre-Treated-HRHER2--Metastatic-Breast-Cancer-Patients-in-the-TROPiCS-02-Study/default.aspx
https://investors.gilead.com/news/news-details/2022/Trodelvy-Significantly-Improves-Overall-Survival-in-Pre-Treated-HRHER2--Metastatic-Breast-Cancer-Patients-in-the-TROPiCS-02-Study/default.aspx
Gilead Sciences, Inc. (Nasdaq: GILD) today announced statistically significant and clinically meaningful results from the second interim analysis of the key secondary endpoint of overall survival (OS) in the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy. Detailed OS results will be presented at an upcoming medical conference. The safety profile for Trodelvy was consistent with prior studies, and no new safety signals emerged in this patient population.
Bei dem Entwicklungspotential und der aktuellen Bewertung verdient die Aktie mehr Aufmerksamkeit.
Joe130978 hat das Wertpapier Gilead Sciences Inc in seinem Wikifolio Stockpicking Worldwide gekauft.
Buy Gilead Sciences Inc
Sell mit Kursziel 46,0
Neueste Beiträge
KongVestor in Kering S.A. diskutieren